Efficacy of antivirals and bivalent mRNA vaccines against SARS-CoV-2 isolate CH.1.1

Uraki, R.; Ito, M.; Kiso, M.; Yamayoshi, S.; Iwatsuki-Horimoto, K.; Sakai-Tagawa, Y.; Furusawa, Y.; Imai, M.; Koga, M.; Yamamoto, S.; Adachi, E.; Saito, M.; Tsutsumi, T.; Otani, A.; Kashima, Y.; Kikuchi, T.; Yotsuyanagi, H.; Suzuki, Y.; Kawaoka, Y.

Uraki, R.; Ito, M.; Kiso, M.; Yamayoshi, S.; Iwatsuki-Horimoto, K.; Sakai-Tagawa, Y.; Furusawa, Y.; Imai, M.; Koga, M.; Yamamoto, S.; Adachi, E.; Saito, M.; Tsutsumi, T.; Otani, A.; Kashima, Y.; Kikuchi, T.; Yotsuyanagi, H.; Suzuki, Y.; Kawaoka, Y..

The Lancet Infectious Diseases ; 2023.

Article in English | EMBASE | ID: covidwho-2284922

Keywords

drug efficacy, letter, nonhuman, Severe acute respiratory syndrome coronavirus 2, antivirus agent, RNA vaccine

Fulltext

XML

Search on Google

Full text: Available Collection: Databases of international organizations Database: EMBASE Topics: Vaccines Language: English Journal: The Lancet Infectious Diseases Year: 2023 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

Search on Google